Our preliminary data also indicates SAR405 decreased the hyper-proliferation and survival of PAVSMC from patients with PAH and reduced pulmonary vascular remodeling in experimental pulmonary hypertension in male mice [20], further indicating the potential clinical uses of VPS34 inhibitors. Here, PIK3C3 is linked to pulmonary hypertension.